Core Viewpoint - A shareholder has filed a securities class action lawsuit on behalf of investors who sold Masonite International Corporation's common stock between June 5, 2023, and February 8, 2024, alleging misrepresentations by the defendants regarding Owens Corning's offers to purchase all of Masonite's outstanding stock [1][4]. Group 1: Lawsuit Details - The lawsuit claims that the defendants made misrepresentations concerning Owens Corning's offers to purchase all of Masonite's outstanding stock [4]. - Investors who wish to serve as lead plaintiffs must file papers by April 7, 2026, and participation as a lead plaintiff is not required to share in any recovery [3]. Group 2: Firm Background - Bernstein Liebhard LLP has recovered over $3.5 billion for its clients since 1993 and has represented both individual investors and large public and private pension funds [5]. - The firm has been recognized for its success in litigating class actions, being named to The National Law Journal's "Plaintiffs' Hot List" thirteen times and listed in The Legal 500 for sixteen consecutive years [5].

NEW YORK, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the common stock of Oracle Corporation (“Oracle” or the “Company”) (NYSE: ORCL) between June 12, 2025 and December 16, 2025, inclusive. What To Do Next: For more information, submit a form at Oracle Corporation Shareholder Class Action Lawsuit, email Investor Relations Manager Peter Allocco at pallocco@bernl ...

Core Viewpoint - A shareholder has filed a securities class action lawsuit against Plug Power Inc. on behalf of investors who purchased securities between January 17, 2025, and November 13, 2025, alleging misrepresentations regarding a loan from the Department of Energy and the company's ability to construct necessary hydrogen production facilities [1][4]. Group 1: Lawsuit Details - The lawsuit claims that the defendants made false statements about a loan from the Department of Energy and Plug Power's capability to build hydrogen production facilities to access the loan funds [4]. - Investors who wish to serve as lead plaintiffs must file papers by April 3, 2026, and participation as a lead plaintiff is not required to share in any recovery [3]. Group 2: Law Firm Background - Bernstein Liebhard LLP has recovered over $3.5 billion for clients since its establishment in 1993 and has represented both individual investors and large public and private pension funds [5]. - The firm has been recognized multiple times for its success in litigating class actions, being named to The National Law Journal's "Plaintiffs' Hot List" thirteen times and listed in The Legal 500 for sixteen consecutive years [5].

Core Viewpoint - A shareholder has filed a securities class action lawsuit against Beyond Meat, Inc. on behalf of investors who purchased or acquired the company's securities between February 27, 2025, and November 11, 2025, alleging misrepresentations regarding the value of certain long-lived assets [1][5]. Group 1: Lawsuit Details - The lawsuit claims that the defendants made misrepresentations concerning the value of certain long-lived assets of Beyond Meat [5]. - Investors who wish to participate in the class action must file papers by March 24, 2026, to serve as lead plaintiff, although participation in any recovery does not require serving in this role [4]. Group 2: Legal Representation - Bernstein Liebhard LLP, the law firm handling the case, has a history of recovering over $3.5 billion for clients and has represented both individual investors and large pension funds [6]. - All representation in this lawsuit is on a contingency fee basis, meaning shareholders will not incur fees or expenses unless there is a recovery [4].

Core Viewpoint - A shareholder has filed a securities class action lawsuit against Vistagen Therapeutics, Inc. on behalf of investors who purchased or acquired the company's common stock between April 1, 2024, and December 16, 2025, alleging misrepresentations related to the company's clinical trial [1][4]. Group 1: Lawsuit Details - The lawsuit claims that the defendants made misrepresentations concerning the Company's Phase 3 PALISADE-3 trial study of fasedienol, which is an investigational pherine candidate for the acute treatment of social anxiety disorder [4]. - Investors who wish to serve as lead plaintiff must file papers by March 16, 2026, and participation as a lead plaintiff is not required to share in any recovery [3]. Group 2: Legal Representation - Bernstein Liebhard LLP, the law firm handling the case, has recovered over $3.5 billion for its clients since 1993 and has a strong track record in class action litigation [5].

Core Viewpoint - Bernstein Liebhard LLP is reminding investors of Beyond Meat, Inc. about a deadline related to a securities fraud class action lawsuit against the company [1]. Group 1: Lawsuit Details - A class action lawsuit has been filed in the United States District Court for the Central District of California on behalf of investors who purchased or acquired Beyond Meat securities between February 27, 2025, and November 11, 2025, alleging violations of the Securities Exchange Act of 1934 [5]. - The lawsuit claims that the defendants made misrepresentations regarding the value of certain long-lived assets of Beyond Meat [6]. Group 2: Legal Actions and Deadlines - Investors wishing to serve as lead plaintiff must file papers by March 24, 2026, and can still share in any recovery without being the lead plaintiff [4]. - All representation in the lawsuit is on a contingency fee basis, meaning shareholders will not incur any fees or expenses [4]. Group 3: Contact Information - Investors can discuss their legal rights and options by visiting the Beyond Meat, Inc. Shareholder Class Action Lawsuit page or contacting Investor Relations Manager Peter Allocco at (212) 951-2030 or pallocco@bernlieb.com [3][9].

Core Insights - Corcept Therapeutics Incorporated is under investigation by Bernstein Liebhard LLP for potential violations of federal securities laws [1][2] - The company received a Complete Response Letter from the FDA regarding its New Drug Application for relacorilant, which led to a significant drop in its stock price [3] Company Developments - On December 31, 2025, Corcept announced that the FDA issued a Complete Response Letter for relacorilant, indicating that while the pivotal GRACE trial met its primary endpoint, additional evidence of effectiveness is required for a favorable benefit-risk assessment [3] - Following the FDA's announcement, Corcept's stock price fell by $35.40 per share, representing a 50.42% decline, closing at $34.80 per share [3] Legal Context - Bernstein Liebhard LLP has a history of recovering over $3.5 billion for clients and has been recognized for its litigation success, indicating a strong capability in handling investor rights cases [4]

Core Viewpoint - A shareholder has filed a securities class action lawsuit against Fermi Inc. for alleged misrepresentations in the Registration Statement related to tenant demand at the Company's Project Matador campus during the Class Period from October 1, 2025, to December 11, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who purchased or acquired Fermi securities either through the October 2025 IPO or during the specified Class Period [1]. - Defendants are accused of making misrepresentations regarding tenant demand, which may have impacted the stock's performance [2]. Group 2: Legal Process - Investors wishing to serve as lead plaintiff must file papers by March 6, 2026, and participation does not require serving as lead plaintiff to share in any recovery [3]. - All legal representation is on a contingency fee basis, meaning shareholders incur no fees or expenses [3]. Group 3: Firm Background - Bernstein Liebhard LLP has recovered over $3.5 billion for clients since 1993 and has represented both individual investors and large pension funds [4]. - The firm has been recognized multiple times for its success in litigating class actions, being named to The National Law Journal's "Plaintiffs' Hot List" and listed in The Legal 500 for several consecutive years [4].

Core Viewpoint - Vistagen Therapeutics, Inc. is facing a securities fraud class action lawsuit, with a deadline for investors to act by March 16, 2026 [1][3][4]. Group 1: Lawsuit Details - The lawsuit was filed in the United States District Court for the Northern District of California on behalf of investors who purchased or acquired Vistagen common stock between April 1, 2024, and December 16, 2025 [4]. - The allegations include misrepresentations made by the Company and certain senior officers regarding the Phase 3 PALISADE-3 trial study of fasedienol, which is being developed for the treatment of social anxiety disorder [5]. Group 2: Investor Actions - Investors who wish to serve as lead plaintiffs must file necessary documents by March 16, 2026, but participation as a lead plaintiff is not required to share in any recovery [3]. - Shareholders are encouraged to contact the Investor Relations Manager for discussions regarding their legal rights and options [2][8]. Group 3: Law Firm Background - Bernstein Liebhard LLP has a history of recovering over $3.5 billion for clients and has been recognized for its success in litigating class actions [6].

NEW YORK, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds Klarna Group plc (“Klarna” or the “Company”) (NYSE: KLAR) investors of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company. Should You Join The Klarna Group Class Action Lawsuit? Do you, or did you, own shares of Klarna Group plc (NYSE: KLAR)?Did you purchase your shares pursuant or traceable to, the Company’s September 2025 IPO?Did you ...